Lupin launches generic potassium chloride oral solution
Lupin is introducing potassium chloride oral solution, 20 mEq/15mL (10%) and 40 mEq/15 mL (20%), having received Food and Drug Administration approval for the drug in August.
The product is the generic equivalent of Genus Lifesciences' potassium chloride oral solution.
It is indicated for the treatment and prophylaxis of hypokalemia with or without metabolic alkalosis in patients for whom dietary management with potassium-rich foods and/or diuretic dose reduction are insufficient.
The product had a market value of approximately $184.95 million, according to June 2018 IQVIA data.
The product is the generic equivalent of Genus Lifesciences' potassium chloride oral solution.
It is indicated for the treatment and prophylaxis of hypokalemia with or without metabolic alkalosis in patients for whom dietary management with potassium-rich foods and/or diuretic dose reduction are insufficient.
The product had a market value of approximately $184.95 million, according to June 2018 IQVIA data.